Effect of antiplatelet agents and tyrosine kinase inhibitors on oxLDL-mediated procoagulant platelet activity.
Zheng TJ, Kohs TCL, Mueller PA, Pang J, Reitsma SE, Parra-Izquierdo I, Melrose AR, Yang L, Choi J, Zientek KD, Sviridov DO, Larson MK, Williams CD, Pamir N, Shatzel JJ, Reddy AP, Kievit P, Remaley AT, Stevens JF, Hinds MT, McCarty OJT, Aslan JE.
Zheng TJ, et al. Among authors: yang l.
Blood Adv. 2023 Apr 25;7(8):1366-1378. doi: 10.1182/bloodadvances.2022007169.
Blood Adv. 2023.
PMID: 36219587
Free PMC article.